Brandon Scalea

Articles

Study Exclusion Criteria Limits Real-World Benefit of Immunotherapy in Lung Cancer

March 6th 2019

Mohammad Jahanzeb, MD, shares the challenges of real-world eligibility for immunotherapy in lung cancer and beyond.

Pivotal Trials Lead to Significant Implications in Gastric/GEJ Cancer

March 6th 2019

Timothy L. Cannon, MD, discusses how pivotal clinical trials have impacted the gastric cancer treatment landscape.

HCC Armamentarium Expands, With Promising Agents on the Horizon

March 5th 2019

Aiwu Ruth He, MD, PhD, discusses the newly crowded treatment landscape of hepatocellular carcinoma and highlights next steps for research.

Sacituzumab Govitecan Shows Early Promise in Urothelial Carcinoma

March 5th 2019

Scott T. Tagawa, MD, discusses the potential of sacituzumab govitecan in advanced urothelial cancers and reflects on progress made in prostate cancer.

Personalized Medicine Is Next Step in Castration-Resistant Prostate Cancer

March 4th 2019

Raoul S. Concepcion, MD, FACS, discusses the clinical implications of the findings from the ARAMIS trial and highlights other therapies that are coming down the pike for the treatment of patients with castration-resistant prostate cancer.

FOLFIRINOX Should Remain Adjuvant Standard for Resectable Pancreatic Cancer

February 26th 2019

Matthew H.G. Katz, MD, FACS, highlights pivotal trials in pancreatic cancer and how these data are shifting the treatment paradigm for these patients.

TNBC Data Encouraging, But Unmet Needs Remain

February 25th 2019

Jane L. Meisel, MD, discusses recent breakthroughs in the previously stagnant field of triple-negative breast cancer and what these advances mean for patients.

Expert Highlights Nivolumab/Ipilimumab Potential in mCRPC

February 23rd 2019

Sumit K. Subudhi, MD, PhD, discusses the promise of the combination of nivolumab and ipilimumab in patients with metastatic castration-resistant prostate cancer and the challenges that lie ahead with this treatment approach.

CLL Research Explores Feasibility of Time-Limited Treatment

February 22nd 2019

Nicole Lamanna, MD, highlights the latest MURANO data in CLL, delving into the need for more studies to test the feasibility of time-limited treatment in this patient population.

SM-88 Safe, Active in Nonmetastatic CRPC

February 22nd 2019

Benjamin A. Gartrell, MD, discusses the promise of SM-88 in this patient population, as well as other therapeutic options that are emerging for various prostate cancer subtypes.

MPNs Pioneer Highlights Long-Lasting Role of Interferon

February 22nd 2019

Richard T. Silver, MD, discusses the history of interferon and shares insight on why the drug still holds its place in the treatment of patients with MPNs.

Bempegaldesleukin/Nivolumab Combo May Address Unmet Need in Metastatic Urothelial Carcinoma

February 18th 2019

Arlene O. Siefker-Radtke, MD, discusses the promising preliminary data with bempegaldesleukin plus nivolumab in patients with metastatic urothelial carcinoma and the next steps for this combination.

Multimodality Approach Best for CNS Disease in NSCLC

February 18th 2019

Sarah B. Goldberg, MD, MPH, sheds light on the complex treatment paradigm for patients with lung cancer who have central nervous system metastases and highlights emerging treatment strategies for those with mesothelioma.

PARP Inhibitors Hold Promise in mCRPC and Biallelic DNA Repair Gene Defects

February 18th 2019

Evan Y. Yu, MD, highlights 2 key studies with PARP inhibitors in metastatic castration-resistant prostate cancer and discussed challenges that need to be addressed in this space in order to further progress.

Brahmer Calls for Better Incorporation of Precision Medicine in Lung Cancer

February 14th 2019

Julie R. Brahmer, MD, discusses advances made with immunotherapy in the lung cancer space, highlights challenges that still need to be addressed, and sheds light on ongoing research designed to determine treatment approaches beyond PD-1/PD-L1 and CTLA-4 inhibition

Wakelee Praises Progress, Points to Next Steps in NSCLC

February 12th 2019

Heather Wakelee, MD, shares insight on the current landscape of lung cancer and discussed how immunotherapy and targeted therapy can be improved for patients with non–small cell lung cancer.

Older Patients With Gastric Cancer May Derive Greater Benefit From Andecaliximab

February 9th 2019

Manish A. Shah, MD, discusses the results of the GAMMA-1 trial and challenges that remain for patients with gastric cancer.

Surgeon Highlights Regional Therapy Approaches for mCRC

February 8th 2019

Byrne Lee, MD, discusses regional treatment strategies for patients with metastatic colorectal cancer.

Cristofanilli Explains Precision of Liquid Biopsies in Advanced Breast Cancer

February 7th 2019

Massimo Cristofanilli, MD, discusses the clinical utility of liquid biopsies—specifically focusing on circulating tumor cells and cell-free DNA—and highlights ongoing research in the space.

Expert Highlights Ongoing Advances in Multiple Myeloma

February 7th 2019

Sarah Holstein, MD, PhD, highlights the vast treatment paradigm of myeloma and shared some considerations for sequencing.